Alsachim SAS
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Revenues | 2.9m | 4.0m | 4.0m | 3.7m | 3.9m | 4.6m |
% growth | - | 38 % | - | (7 %) | 4 % | 18 % |
EBITDA | 1.1m | <1m | <1m | (<1m) | (<1m) | - |
% EBITDA margin | 36 % | 7 % | 11 % | (13 %) | (6 %) | - |
Profit | <1m | <1m | <1m | <1m | (<1m) | (<1m) |
% profit margin | 29 % | 2 % | 2 % | 6 % | (22 %) | (15 %) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | Growth Equity VC | |
N/A | Acquisition | ||
Total Funding | - |
Recent News about Alsachim SAS
EditAlsachim is a prominent player in the synthesis of stable labeled internal standards, boasting over 15 years of expertise in the field. The company specializes in producing high-quality labeled compounds, such as 13C, 2H, 15N, 18O, and 34S, which are essential for precise quantification in LC-MS/MS analyses. Alsachim serves a diverse clientele, including pharmaceutical companies, research institutions, and analytical laboratories, providing them with custom synthesis and chemical development services. Operating in the global market, Alsachim ensures the highest quality and purity of its products by controlling the entire process from research and development to manufacturing and delivery. The company's business model revolves around offering a comprehensive catalog of over 3,000 products, including unique compounds, and generating revenue through direct sales and custom projects. Alsachim's team of scientists and advanced analytical instruments, such as NMR, HPLC, GC, and MS, enable them to meet the specific needs of their clients efficiently. The company is committed to building long-term relationships by understanding and addressing client requirements promptly.
Keywords: stable labeled standards, LC-MS/MS, custom synthesis, chemical development, pharmaceutical research, analytical laboratories, high-quality compounds, global market, advanced instruments, client-focused.